ReviewInternational journal of molecular sciences2019
The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review.Journal of neurovirology · 2022Pooled it
- Anticipating Clinical Onset in Multiple Sclerosis: Challenges and Opportunities.Journal of personalized medicine · 2025Review
- Childhood and adolescence factors and multiple sclerosis: results from the German National Cohort (NAKO).BMC neurology · 2024Article
- Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review.Cellular and molecular neurobiology · 2023Review
- Review
- Higher Dietary Acid Load Might Be a Potent Derivative Factor for Multiple Sclerosis: The Results from a Case-Control Study.Nutrients · 2023Article
- Navigating the journey of multiple sclerosis management in Africa, overcoming hurdles and harnessing opportunities: a review.Annals of medicine and surgery (2012) · 2023Article
- A Deep Learning Approach for Predicting Multiple Sclerosis.Micromachines · 2023Article
- Viral Immune signatures from cerebrospinal fluid extracellular vesicles and particles in HAM and other chronic neurological diseases.Frontiers in immunology · 2023Article
- Interaction of the viral infectious agents in the development and exacerbation of the multiple sclerosis.Le infezioni in medicina · 2023Review
- Lack of association between C282Y and H63D polymorphisms in the hemochromatosis gene and risk of multiple sclerosis: A meta-analysis.Biomedical reports · 2022Article
- Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.Frontiers in immunology · 2022Review
- Article
- MicroRNAs, Multiple Sclerosis, and Depression.International journal of molecular sciences · 2021Review
- Deficits in Early Sensory and Cognitive Processing Are Related to Phase and Nonphase EEG Activity in Multiple Sclerosis Patients.Brain sciences · 2021Article
- Serum Vitamin D Level among Multiple Sclerosis Patients in the Tropics: Experience from a Private Clinic in Addis Ababa, Ethiopia.Ethiopian journal of health sciences · 2021Observational
- Epstein-Barr Virus and Neurological Diseases.Frontiers in molecular biosciences · 2021Review
- PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.International journal of molecular sciences · 2020Article
- Long-term effects of latitude, ambient temperature, and ultraviolet radiation on the incidence of multiple sclerosis in two cohorts of US women.Environmental epidemiology (Philadelphia, Pa.) · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multiple sclerosis (MS) is a chronic debilitating inflammatory disease of unknown ethology targeting the central nervous system (CNS). MS has a polysymptomatic onset and is usually first diagnosed between the ages of 20⁻40 years. The pathology of the disease is characterized by immune mediated demyelination in the CNS. Although there is no clinical finding unique to MS, characteristic symptoms include sensory symptoms visual and motor impairment. No definitive trigger for the development of MS has been identified but large-scale population studies have described several epidemiological risk factors for the disease. This list is a confusing one including latitude, vitamin D (vitD) levels, genetics, infection with Epstein Barr Virus (EBV) and endogenous retrovirus (ERV) reactivation. This review will look at the evidence for each of these and the potential links between these disparate risk factors and the known molecular disease pathogenesis to describe potential hypotheses for the triggering of MS pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.